An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS

P. A. Calabresi; J. L. Wilterdink; J. M. Rogg; P. Mills; A. Webb; K. A. Whartenby

doi:10.1212/WNL.58.2.314

An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS

P. A. Calabresi, J. L. Wilterdink, J. M. Rogg, P. Mills, A. Webb, K. A. Whartenby

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon β-1a (IFNβ-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNβ monotherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.

Original language	English (US)
Pages (from-to)	314-317
Number of pages	4
Journal	Neurology
Volume	58
Issue number	2
DOIs	https://doi.org/10.1212/WNL.58.2.314
State	Published - Jan 22 2002
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.58.2.314

Cite this

@article{1a5079c321a44d0fb570db9969f3973a,

title = "An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS",

abstract = "An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon β-1a (IFNβ-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNβ monotherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.",

author = "Calabresi, {P. A.} and Wilterdink, {J. L.} and Rogg, {J. M.} and P. Mills and A. Webb and Whartenby, {K. A.}",

year = "2002",

month = jan,

day = "22",

doi = "10.1212/WNL.58.2.314",

language = "English (US)",

volume = "58",

pages = "314--317",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS

AU - Calabresi, P. A.

AU - Wilterdink, J. L.

AU - Rogg, J. M.

AU - Mills, P.

AU - Webb, A.

AU - Whartenby, K. A.

PY - 2002/1/22

Y1 - 2002/1/22

N2 - An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon β-1a (IFNβ-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNβ monotherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.

AB - An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon β-1a (IFNβ-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNβ monotherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.

UR - http://www.scopus.com/inward/record.url?scp=0037154138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037154138&partnerID=8YFLogxK

U2 - 10.1212/WNL.58.2.314

DO - 10.1212/WNL.58.2.314

M3 - Article

C2 - 11805267

AN - SCOPUS:0037154138

SN - 0028-3878

VL - 58

SP - 314

EP - 317

JO - Neurology

JF - Neurology

IS - 2

ER -

An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this